Other Consolidated Financial Statement Detail

Other Income (Expense), Net

Components of other income (expense), net, are summarized as follows:



	For the Three Months Ended September 30,						For the Nine Months Ended September 30,
(In millions)	2016			2015			2016			2015
Interest income	$	16.4		$	5.4		$	43.0		$	13.0
Interest expense	(66.0		)	(15.6		)	(195.2		)	(28.1		)
Gain (loss) on investments, net	0.8			1.1			(0.3		)	(0.3		)
Foreign exchange gains (losses), net	(4.9		)	(4.3		)	(2.6		)	(18.8		)
Other, net	(4.4		)	(2.0		)	(14.3		)	(7.1		)
Total other income (expense), net	$	(58.1	)	$	(15.4	)	$	(169.4	)	$	(41.3	)

Other Current Assets

Other current assets includes prepaid taxes totaling approximately $725.3 million and $550.6 million as of September 30, 2016 and December 31, 2015, respectively.

Accrued Expenses and Other

Accrued expenses and other consists of the following:



(In millions)	As of September 30, 2016		As of December 31, 2015
Current portion of contingent consideration obligations and milestones	$	570.5	$	504.7
Revenue-related reserves for discounts and allowances	383.0		518.1
Employee compensation and benefits	282.7		270.8
Royalties and licensing fees	209.0		167.9
Other	566.8		635.3
Total accrued expenses and other	$	2,012.0	$	2,096.8

Pricing of TYSABRI in Italy - AIFA

In the fourth quarter of 2011, Biogen Italia SRL, our Italian subsidiary, received a notice from the Italian National Medicines Agency (Agenzia Italiana del Farmaco or AIFA) that sales of TYSABRI after mid-February 2009 exceeded a reimbursement limit established pursuant to a Price Determination Resolution (Price Resolution) granted by AIFA in December 2006. In January 2012, we filed an appeal in the Regional Administrative Tribunal of Lazio (Il Tribunale Amministrativo Regionale per il Lazio) in Rome, Italy seeking a ruling that the reimbursement limit in the Price Resolution should apply as written to only "the first 24 months" of TYSABRI sales, which ended in mid-February 2009. That appeal is still pending.

In June 2014, AIFA approved a resolution affirming that there is no reimbursement limit from and after February 2013. As a result, we recognized $53.5 million of TYSABRI revenues related to the periods beginning February 2013 that were previously deferred. AIFA and Biogen Italia SRL are still discussing a possible resolution for the period from February 2009 through January 2013. We have approximately EUR75 million recorded as accrued expenses and deferred revenue included in our long-term liabilities in our condensed consolidated balance sheet for this matter as of September 30, 2016 and December 31, 2015.

For additional information relating to our agreement with AIFA relating to sales of TYSABRI in Italy, please read Note 17, Other Consolidated Financial Statement Detail to our consolidated financial statements included in our 2015 Form 10-K.